ClinicalTrials.gg
RecruitingNCT06502873ELITEUpdated Jan 28, 2026

Setting up a Cohort of Patients With Inflammatory Bowel Disease and a Cohort of Patients Without Chronic Inflammatory Bowel Disease

An interventional study of biological samples collection in Inflammatory Bowel Disease (IBD), sponsored by Artialis. Recruiting at 1 site in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-28.

Sponsored by Artialis · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Jun 2024; still recruiting 2 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 61 studies in Inflammatory Bowel Diseases with a site in Belgium — 13 open to participants now, 18 under way, 5 of them phase 3. Inflammatory Bowel Diseases · Belgium.

Planned enrollment
31st of 50
120 · median 144
Started
2024
with 5 others
No phase
6 of 61
4 open now
Primary completion
2026-09
later than 8 of 17 live
Registered
53rd of 61
by date

Among the 61 studies in Inflammatory Bowel Diseases with a site in Belgium, this one is the 31st largest by planned enrollment of the 50 interventional ones that give a count, is one of 6 that started in 2024, is one of 6 with no phase, reaches primary completion later than 8 of the 17 other live ones, and was the 53rd registered.

Inflammatory Bowel Diseases

1,555 studies on the registry are indexed under Inflammatory Bowel Diseases; 425 are open to participants now.

Browse Inflammatory Bowel Diseases studies →

Open to participants now

13 of the 61 studies in Inflammatory Bowel Diseases with a site in Belgium are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →

Who these studies take

Of the 276 Inflammatory Bowel Diseases studies recruiting now, 134 (49%) set no upper age limit and 114 (41%) stop at 75 or younger; 75 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 61 studies in Inflammatory Bowel Diseases with a site in Belgium, or all of them as a file.
02

Study summary

The objective of this study is to constitute cohorts of IBD versus non-IBD patients to identify (a) new biomarker(s) of intestinal dysbiosis associated with inflammatory bowel disease, and develop a prototype for assaying such marker(s) in blood.

03

Conditions studied

  • Inflammatory Bowel Disease (IBD)

Keywords

  • cohort
  • BEV
  • intestinal dysbiosis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

General criteria:

  • Male or female ≥ 18 years old
  • Able to follow the instructions of the study
  • Having signed an

Specific for Crohn cohort:

  • A confirmed diagnosis of IBD
  • Rectal or colonic or ileocolic involvement
  • Patients with CD presenting inflammatory flare and disease extent in the colon or ileocolic region with:
  • A clinical activity defined by an average of four or more instances of very soft or liquid stools daily or an abdominal pain score of 2 or more OR a CDAI (CD Activity Index) ≥ 220 OR a Harvey-Bradshaw Index > 8 OR a faecal calprotectin ≥ 250 µg/g And
  • A endoscopic activity defined by a SES-CD (Simple Endoscopic Score for Crohn Disease) ≥ 6 or a CDEIS (CD Endoscopic Index score) ≥ 7
  • Patients with UC presenting inflammatory flare with:

A clinical activity defined by a modified Mayo score ≥ 3 OR a Simple Clinical Colitis Activity Index ≥5 OR Patient Reported Outcome (PRO2) ≥ 4 with a subscore of rectal bleeding ≥1 OR a faecal calprotectin ≥ 250 µg/g AND An endoscopic activity defined by a Mayo endoscopic sub-score ≥ 2

Specific for Control cohort:

Patient with no colonic lesion(s) visible during the endoscopical examination (neither Crohn's nor other colitis nor cancer)

Exclusion criteria

Exclusion Criteria:

General criteria:

  • Commercial Pharmaceutical probiotic administration within the previous month
  • Treatment with antibiotics (whatever the route of administration) within last 3 months
  • Non-remission Cancer or in remission for less than 6 months
  • Any to colonoscopy and/or , left to PI discretion
  • Under guardianship or judiciable protection
  • Pregnant or breastfeeding women
  • Currently participating or having participated in the last 3 months to a clinical study with medicine or food supplement

Specific for Crohn cohort:

  • Crohn disease localized only in Ileum
  • Inflammatory colon pathology other than Crohn's (infectious, drug-induced,…)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Other
    Inflammatory bowel disease cohort

    60 patients diagnosed with colonic inflammatory bowel disease

    Procedure: biological samples collection

  • Other
    Control cohort

    60 control patients without inflammatory bowel diseases

    Procedure: biological samples collection

Interventions

  • Procedurebiological samples collection

    Collection of biological samples from the same cohorts: faeces, serum, intestinal biopsies

06

What researchers measure

Primary outcomes

  1. Number of patients recruited in each cohort

    60 patients in IBD cohort and 60 patients in control cohort

    Time frame: 27 months

  2. number of faeces samples collected in each cohort

    60 patients in IBD cohort and 60 patients in control cohort

    Time frame: 27 months

  3. Number of plasma samples collected in each cohort

    60 patients in IBD cohort and 60 patients in control cohort

    Time frame: 27 months

  4. Number of biopsy samples collected in each cohort

    60 patients in IBD cohort and 60 patients in control cohort with 4 colonic biopsies/ patient

    Time frame: 27 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2024 (actual). Primary completion is estimated for Sep 2026, 27 months after the start.

Of 299 interventional studies with no phase under Inflammatory Bowel Diseases, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 50. This study's planned 27 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 2, 2024
First posted
Jul 16, 2024
StartActual
Jun 28, 2024
Primary completionEst.
Sep 30, 2026
CompletionEst.
Dec 31, 2026
Last update
Jan 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06502873
Lead sponsor
Artialis
Responsible party
Sponsor
First posted
Jul 16, 2024
Start date
Jun 28, 2024
Primary completion
Sep 30, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jan 28, 2026

Study contacts

Bérénice Costes
Contact
berenice.costes@artialis.com
042670888
Catherine Van Kemseke, MD
principal investigator · Centre Hospitalier Universitaire de Liege

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion